DavidCPortnoyMD
Oncology • Germantown, TNAssistant Professor, Medicine-Hematology, University of Tennessee Health Science Center College of Medicine
Dr. Portnoy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
7945 Wolf River Blvd
Germantown, TN 38138Phone+1 901-683-0055Fax+1 901-685-9718
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
SUNY Upstate Medical UniversityClass of 2003
Certifications & Licensure
MS State Medical License 2009 - 2025
TN State Medical License 2009 - 2025
MA State Medical License 2006 - 2010
PA State Medical License 2003 - 2006
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
Clinical Trials
- Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer Start of enrollment: 2013 Apr 01
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Publications & Presentations
PubMed
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.Reinhard Dummer, Caroline Robert, Richard A Scolyer, Janis M Taube, Michael T Tetzlaff
Nature Medicine. 2025-01-01 - Rosai-Dorfman disease of the cauda equina: illustrative case.William Mangham, Emal Lesha, Elsa Nico, Kaan Yagmurlu, Christopher P Golembeski
Journal of Neurosurgery. Case Lessons. 2024-01-22 - 46 citationsIpilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial.Ari VanderWalde, Shay L Bellasea, Kari L Kendra, Nikhil I Khushalani, Katie M Campbell
Nature Medicine. 2023-09-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
